| 001 | 294574 | ||
| 005 | 20250316015552.0 | ||
| 024 | 7 | _ | |a 10.1093/neuonc/noae228 |2 doi |
| 024 | 7 | _ | |a pmid:39556024 |2 pmid |
| 024 | 7 | _ | |a 1522-8517 |2 ISSN |
| 024 | 7 | _ | |a 1523-5866 |2 ISSN |
| 024 | 7 | _ | |a altmetric:172118384 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2024-02349 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Laemmerer, Anna |b 0 |
| 245 | _ | _ | |a Alternative lengthening of telomere-based immortalization renders H3G34R -mutant diffuse hemispheric glioma hypersensitive to PARP inhibitor combination regimens. |
| 260 | _ | _ | |a Oxford |c 2025 |b Oxford Univ. Press |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1741680683_17954 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a 2025 Mar 7;27(3):811-827 |
| 520 | _ | _ | |a Diffuse hemispheric glioma, H3G34R/V-mutant (DHG-H3G34) is characterized by poor prognosis and lack of effective treatment options. DHG-H3G34R further harbor deactivation of Alpha-Thalassemia/Mental Retardation Syndrome X-linked protein (ATRX; DHG-H3G34R_ATRX) suggesting a unique interaction of these two oncogenic alterations. In this study, we dissect their cell biological interplay, investigate the impact on telomere stabilization and, consequently, validate a targeted therapy approach.We characterized patient-derived primary pediatric high-grade glioma (pHGG) models for telomere-maintenance mechanisms, DNA damage stress (including protein expression, pH2AX/Rad51 foci, cell-cycle arrest) and their sensitivity towards poly-ADP polymerase inhibitor (PARPi) combinations. Human induced pluripotent stem cells (iPSCs) were used for modelling the disease. The anticancer activity of PARPi combinations in vivo was studied in Chorioallantoic Membrane (CAM) and orthotopic in vivo experiments. Finally, we treated a DHG-H3G34R_ATRX patient with a PARPi combination therapy.We elaborate that alternative lengthening of telomeres (ALT) is a key characteristic of DHG-H3G34R_ATRX. A dominant cooperative effect between H3G34R and ATRX loss in ALT activation also became apparent in iPSCs, which endogenously exert telomerase activity. In both, patient-derived DHG-H3G34R_ATRX models and H3G34R+/ATRX- iPSCs, the ALT phenotype was associated with increased basal DNA damage stress, mediating synergistic susceptibility towards PARPi (talazoparib, niraparib) combinations with topoisomerase-I inhibitors (topotecan, irinotecan). In a first-of-its-kind case, treatment of a DHG-H3G34R_ATRX patient with the brain-penetrant PARP inhibitor niraparib and topotecan resulted in a significant tumor reduction.Our preclinical and clinical data strongly support the further development of PARPis together with DNA damage stress-inducing treatment regimens for DHG-H3G34R_ATRX. |
| 536 | _ | _ | |a 312 - Funktionelle und strukturelle Genomforschung (POF4-312) |0 G:(DE-HGF)POF4-312 |c POF4-312 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a ATRX |2 Other |
| 650 | _ | 7 | |a DNA damage |2 Other |
| 650 | _ | 7 | |a Diffuse hemispheric glioma |2 Other |
| 650 | _ | 7 | |a H3G34R |2 Other |
| 650 | _ | 7 | |a PARP inhibitor |2 Other |
| 700 | 1 | _ | |a Lehmann, Christian |b 1 |
| 700 | 1 | _ | |a Mayr, Lisa |b 2 |
| 700 | 1 | _ | |a Bruckner, Katharina |b 3 |
| 700 | 1 | _ | |a Gabler, Lisa |b 4 |
| 700 | 1 | _ | |a Senfter, Daniel |b 5 |
| 700 | 1 | _ | |a Meyer, Philipp |b 6 |
| 700 | 1 | _ | |a Balber, Theresa |b 7 |
| 700 | 1 | _ | |a Pirker, Christine |b 8 |
| 700 | 1 | _ | |a Jaunecker, Carola N |b 9 |
| 700 | 1 | _ | |a Kirchhofer, Dominik |b 10 |
| 700 | 1 | _ | |a Vician, Petra |b 11 |
| 700 | 1 | _ | |a Griesser, Michelle |b 12 |
| 700 | 1 | _ | |a Spiegl-Kreinecker, Sabine |b 13 |
| 700 | 1 | _ | |a Schmook, Maria T |b 14 |
| 700 | 1 | _ | |a Traub-Weidinger, Tatjana |b 15 |
| 700 | 1 | _ | |a Kuess, Peter |b 16 |
| 700 | 1 | _ | |a Eckert, Franziska |b 17 |
| 700 | 1 | _ | |a Federico, Aniello |0 P:(DE-He78)32c5110cd42ee8a96b18a3e8909bd0a9 |b 18 |u dkfz |
| 700 | 1 | _ | |a Madlener, Sibylle |b 19 |
| 700 | 1 | _ | |a Stepien, Natalia |b 20 |
| 700 | 1 | _ | |a Robl, Bernhard |b 21 |
| 700 | 1 | _ | |a Baumgartner, Alicia |b 22 |
| 700 | 1 | _ | |a Hainfellner, Johannes A |b 23 |
| 700 | 1 | _ | |a Dieckmann, Karin |b 24 |
| 700 | 1 | _ | |a Dorfer, Christian |0 0000-0002-1843-7732 |b 25 |
| 700 | 1 | _ | |a Roessler, Karl |b 26 |
| 700 | 1 | _ | |a Corsini, Nina S |b 27 |
| 700 | 1 | _ | |a Holzmann, Klaus |0 0000-0003-4077-3377 |b 28 |
| 700 | 1 | _ | |a Schmidt, Wolfgang M |b 29 |
| 700 | 1 | _ | |a Peyrl, Andreas |0 0000-0002-5736-8231 |b 30 |
| 700 | 1 | _ | |a Azizi, Amedeo A |0 0000-0002-1347-6644 |b 31 |
| 700 | 1 | _ | |a Haberler, Christine |0 0000-0003-1016-0545 |b 32 |
| 700 | 1 | _ | |a Beck, Alexander |b 33 |
| 700 | 1 | _ | |a Pfister, Stefan M |0 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9 |b 34 |u dkfz |
| 700 | 1 | _ | |a Schueler, Julia |b 35 |
| 700 | 1 | _ | |a Loetsch-Gojo, Daniela |b 36 |
| 700 | 1 | _ | |a Knoblich, Jürgen A |b 37 |
| 700 | 1 | _ | |a Berger, Walter |b 38 |
| 700 | 1 | _ | |a Gojo, Johannes |b 39 |
| 773 | _ | _ | |a 10.1093/neuonc/noae228 |g p. noae228 |0 PERI:(DE-600)2094060-9 |n 3 |p 811-827 |t Neuro-Oncology |v 27 |y 2025 |x 1522-8517 |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:294574 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 18 |6 P:(DE-He78)32c5110cd42ee8a96b18a3e8909bd0a9 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 34 |6 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-312 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Funktionelle und strukturelle Genomforschung |x 0 |
| 914 | 1 | _ | |y 2024 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2023-10-24 |w ger |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b NEURO-ONCOLOGY : 2022 |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0320 |2 StatID |b PubMed Central |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-10-24 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2023-10-24 |
| 915 | _ | _ | |a IF >= 15 |0 StatID:(DE-HGF)9915 |2 StatID |b NEURO-ONCOLOGY : 2022 |d 2023-10-24 |
| 920 | 1 | _ | |0 I:(DE-He78)B062-20160331 |k B062 |l B062 Pädiatrische Neuroonkologie |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)HD01-20160331 |k HD01 |l DKTK HD zentral |x 1 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)B062-20160331 |
| 980 | _ | _ | |a I:(DE-He78)HD01-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|
guest ::